Breaking New Ground in Chronic Pain Relief: Advancements in Drug Discovery for Trigeminal Neuralgia

Trigeminal neuralgia (TN) is a severe chronic pain disorder with limited treatment options. Our recent webinar brought together experts to explore its mechanisms and discuss innovative therapeutic strategies. We were honoured to hear from Professor Michael Gold, PhD, from the University of Pittsburgh, who shared key findings on TN's unique pathology and the challenges of modelling the disorder. He highlighted the difficulties in replicating TN in animal studies, differences in gene expression between trigeminal and somatic nerves, and the role of specific genes in action potential propagation. His insights emphasized the complexity of TN and the need for better preclinical models to advance treatment development. Anthony M. Rush, PhD, Director of Neuroscience at Metrion, presented on the role of pain drug discovery assays in advancing novel treatments. He emphasised the importance of translational assays in pain therapeutics and how sensory neuron-based assays can enhance the success rate of drug candidates. His talk underscored the critical role that robust preclinical assays play in identifying and validating new pain treatments. We extend our sincere gratitude to Professor Michael Gold and Dr. Anthony M. Rush for sharing their expertise and to all attendees for their engagement and insightful questions. Your participation contributes to ongoing advancements in the field of chronic pain research.
Recommended Publications
Latest Publications
Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders

This webinar presents the patient perspective, electrophysiological research, and technologies used as we work towards a potential treatment for KCNC1-related disorders.

In Vitro Assessment of Cardiac Risk in Drug Discovery

Clear decision-making data for your project team is vital to ensure you avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.

Hear from industry experts, Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company) and Steve Jenkinson (Metrion).

View All
Breaking New Ground in Chronic Pain Relief: Advancements in Drug Discovery for Trigeminal Neuralgia
Rare Disease Day 2025: Ion channels in rare diseases
View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram